Analysts See $-0.19 EPS for Leju Holdings Ltd (ADR) (LEJU); Cytokinetics Has 2.94 Sentiment

November 15, 2017 - By Linda Rogers

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The company has market cap of $606.20 million. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It currently has negative earnings. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analysts expect Leju Holdings Ltd (ADR) (NYSE:LEJU) to report $-0.19 EPS on November, 28 before the open.They anticipate $0.34 EPS change or 226.67% from last quarter’s $0.15 EPS. After having $-0.64 EPS previously, Leju Holdings Ltd (ADR)’s analysts see -70.31% EPS growth. The stock increased 10.32% or $0.16 during the last trading session, reaching $1.71. About shares traded. Leju Holdings Ltd (ADR) (NYSE:LEJU) has declined 28.96% since November 15, 2016 and is downtrending. It has underperformed by 45.66% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $68,093 activity.

Bvf Inc Il holds 3.74% of its portfolio in Cytokinetics, Inc. for 1.99 million shares. Ironwood Investment Management Llc owns 114,262 shares or 1% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 0.45% invested in the company for 217,990 shares. The Massachusetts-based Bogle Investment Management L P De has invested 0.36% in the stock. Lansdowne Partners (Uk) Llp, a United Kingdom-based fund reported 2.65 million shares.

Ratings analysis reveals 100% of Cytokinetics’s analysts are positive. Out of 2 Wall Street analysts rating Cytokinetics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $21.0 while the high is $22.0. The stock’s average target of $21.50 is 91.11% above today’s ($11.25) share price. CYTK was included in 2 notes of analysts from December 16, 2016. The firm has “Strong Buy” rating given on Monday, February 6 by Needham. Cantor Fitzgerald initiated Cytokinetics, Inc. (NASDAQ:CYTK) rating on Friday, December 16. Cantor Fitzgerald has “Overweight” rating and $21.0 target.

The stock decreased 3.02% or $0.35 during the last trading session, reaching $11.25. About shares traded. Cytokinetics, Inc. (CYTK) has risen 88.33% since November 15, 2016 and is uptrending. It has outperformed by 71.63% the S&P500.

Analysts await Cytokinetics, Inc. (NASDAQ:CYTK) to report earnings on February, 15. They expect $-0.77 earnings per share, down 581.25% or $0.93 from last year’s $0.16 per share. After $-0.60 actual earnings per share reported by Cytokinetics, Inc. for the previous quarter, Wall Street now forecasts 28.33% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>